|
[1]WANG HX, JIN S.Experience of Professor Jin Shi in treatment of primary biliary cirrhosis[J].JiLin J Tradit Chin Med, 2011, 31 (1) :37-38. (in Chinese) 王红霞, 金实.金实教授治疗原发性胆汁性肝硬化经验[J].吉林中医药, 2011, 31 (1) :37-38.
|
|
[2]ZHONG RQ, QIAN Z.Study and prospect of the pathogenesis of primary biliary cirrhosis[J].Chin J Lab Diagn, 2008, 12 (5) :691-694. (in Chinese) 仲人前, 钱峥.原发性胆汁性肝硬化发病机制研究及展望[J].中国实验诊断学, 2008, 12 (5) :691-694.
|
|
[3]XUAN L, DONG ZH.Research progress in traditional Chinese in primary biliary cirrhosis[J].J Med Res, 2011, 40 (5) :15-17. (in Chinese) 宣磊, 董振华.原发性胆汁性肝硬化中医药研究进展[J].医学研究杂志, 2011, 40 (5) :15-17.
|
|
[4]CROSIGNANI A, BATTEZZATI PM, INVEMIZZI P, et al.Clinical features and management of primary biliary cirrhosis[J].World J Gastroenterol, 2008, 14 (21) :3313-3327.
|
|
[5]ZHANG FK.Progress in the treatment of primary biliary cirrhosis[J].Chin J Gastroenterol Hepatol, 2012, 19 (8) :770-773. (in Chinese) 张福奎.原发性胆汁性肝硬化的治疗进展[J].胃肠病学和肝病学杂志, 2012, 19 (8) :770-773.
|
|
[6]DUAN WJ, YOU H.Therapy advances in primary cirrhosis[J].J Chin Hepatol, 2011, 27 (6) :581-583. (in Chinese) 段维佳, 尤红.原发性胆汁性肝硬化的治疗进展[J].临床肝胆病杂志, 2011, 27 (6) :581-583.
|
|
[7]SMITH T, BEFELER AS.Hign-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis[J].Curr Gastroenterol Rep, 2007, 9 (1) :54-59.
|
|
[8]IKEGAMI T, MATSUZAKI Y.Ursodeoxycholic acid:Mechanism of action and noveI clinical applications[J].Hepatol Res, 2008, 38 (2) :123-131.
|
|
[9]GAO PK.Clinical analysis of primary biliary cirrhosis[J].Chin Pract Med, 2009, 4 (1) :116-118. (in Chinese) 高荣凯.原发性胆汁性肝硬化临床分析[J].中国实用医药, 2009, 4 (1) :116-118.
|
|
[10]LINDOR KD, GERSHWIN ME, POUPON R, et al.Primary biliary cirrhosis[J].Hepatology, 2009, 50 (1) :291-308.
|
|
[11]CHARATCHAROENWITTHAYA P, TALWALKAR JA, ANGULO P, et al.Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid[J].Dig Dis Sci, 2010, 55 (2) :476-483.
|
|
[12]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of cholestatic liver diseases[J].HepatoI, 2009, 51 (2) :237-267.
|
|
[13] HAN Y, ZHU JY.Therapy for refractory primary biliary cirrhosis[J].Chin J Hepatol, 2012, 20 (5) :330-332.韩英, 朱疆依.难治性原发性胆汁性肝硬化的治疗[J].中华肝脏病杂志, 2012, 20 (5) :330-332.
|
|
[14]DUAN WJ, JIA JD.EASL clinical practice guidelines:management of cholestatic liver diseases (2009) [J].J Clin Hepatol, 2009, 25 (6) :403-406. (in Chinese) 段维佳, 贾继东.2009年欧洲肝病学会胆汁淤积性肝病的诊治指南简介[J].临床肝胆病杂志, 2009, 25 (6) :403-406.
|
|
[15]CHAZOUILLRES O, WENDUM D, SERFATY L, et al.Long term outcome and response to therapy of patients with primary-autoimmune hepatitis overlap syndrome[J].Hepatol, 2006, 44 (2) :400-406.
|
|
[16]ANGULO P, JORGENSEN RA, KEACH JC, et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid[J].Hepatology, 2000, 31 (2) :318-323.
|
|
[17]KAPLAN MM, BONDER A, RUTHAZER R, et al.Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid[J].Dig Dis Sci, 2010, 55 (11) :3207-3217.
|
|
[18]BACH N, BODIAN C, BODENHEIMER H, et al.Methotrexate therapy for primary biliary cirrhosis[J].Am J Gastroenterol, 2003, 98 (1) :187-193.
|
|
[19]HAZZAN R, TUR-KASPA R.Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid[J].J Clin Gastroenterol, 2010, 44 (5) :371-373.
|
|
[20]HAN XF, WANG QX, LIU Y, et al.Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy[J].J Dig Dis, 2012, 13 (4) :219-224.
|
|
[21]FIOMCCI S, RIZZO G, ANTONELLI E, et al.A famesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metallo-proteinase inhibitor-I and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of fiver fibrosis[J].J Pharmaeol Exp Ther, 2005, 314 (2) :584-595.
|
|
[22]LINDOR KD.Farnesoid X receptor agonists for primary biliary cirrhosis[J].Curr Opin Gastroenterol, 2011, 27 (3) :285-288.
|
|
[23] PITTINGER M, MACKAY A, BECK S, et al.Multilineage potential of adult human mesenchymal stem cells[J].Science, 1999, 284:143-147.
|
|
[24]van POLL D, PAREKKADAN B, CHO CH, et al.Mesenehymal stem cell-derived molecules directly modulate hepatacellular death and regeneration in vitro and in vivo[J].Hepatology, 2008, 47 (5) :1634-1643.
|
|
[25]ABDEL AZIZ MT, ATTA HM, MAHFOUZ S, et aI.Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis[J].Clin Biochemistry, 2007, 40 (12) :893-899.
|
|
[26] PAREKKADAN B, van POLL D, SUGANUMA K, et al.Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure[J].PLoS ONE, 2007, 2 (9) :e941.
|
|
[27]CHAMBERLAIN J, YAMAGAMI T, COLLETTI E, et al.Efficient generation of human hepatocytes by the intrahepatic delivery of clonal human mesenchymal stem cells in fetal sheep[J].Hepatology, 2007, 46 (6) :1935-1945.
|
|
[28]AURICH I, MUELLER LP, AURICH H, et al.Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers[J].Cut, 2007, 56 (3) :405-415.
|
|
[29]MOHAMADNEJAD M, ALIMOGHADDAM K, MOHYEDDINBONAB M, et al.Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis[J].Arch Iranian Med, 2007, 10 (4) :459-466.
|
|
[30]DHIRAPONG A, LLEO A, YANG GX, et al.B cell depletion therapy exacerbates murine primary biliary cirrhosis[J].World J Gastroenterol, 2012, 18 (30) :3938-3940.
|
|
[31]TSUDA M, MORITOKI Y, LIAN ZX, et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology, 2012, 55 (2) :512-521.
|
|
[32]DHIRAPONG A, LLEO A, YANG GX, et al.B cell depletion therapy exacerbates murine primary biliary cirrhosis[J].Hepatology, 2011, 53 (2) :527-535.
|
|
[33]KUROSAKI T.Paradox of B cell-targeted therapies[J].Clin Invest, 2008, 118 (10) :3260-3263.
|
|
[34]PESCOVITZ MD, GREENBAUM CJ, KRAUSE-STEINRAUF H, et al.Rituximab, B-lymphocyte depletion, and preservation of beta-cell function[J].N Engl J Med, 2009, 361 (22) :2143-2152.
|
|
[35]POLIDO-PEREIRA J, RODRIGUES AM, CANHO H, et al.Primary biliary cirrhosis in a rheumatoid arthritis patient treated with rituximab, a case-based review[J].Clin Rheumatol, 2012, 31 (2) :385-389.
|
DownLoad: